ArticleEuropean journal of nuclear medicine and molecular imaging2018
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Efficacy and Safety ofFrontiers in oncology · 2022Pooled it
- Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.European journal of nuclear medicine and molecular imaging · 2026Trial
- Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.Prostate cancer and prostatic diseases · 2026Trial
- Impact of Concomitant Hormone Therapy on the Diagnostic Performance ofThe Prostate · 2025Trial
- Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated withEuropean journal of nuclear medicine and molecular imaging · 2020Trial
- First-in-human evaluation of [Annals of medicine · 2026Article
- PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.European urology open science · 2026Review
- The feasibility of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.The oncologist · 2026Review
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- Can Tc-99m-PSMA SPECT/CT Be Used as Accessible Alternative for Diagnosis of Biochemically Recurrent Prostate Cancer? A Prospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- The impact of short-term non-steroidal androgen antagonist therapy on PSMA expression and tumor cellularity studied with dynamic [EJNMMI research · 2025Article
- PSMA-Directed Theranostics in Prostate Cancer.Biomedicines · 2025Review
- The effect of androgen blockade on [EJNMMI research · 2025Article
- Applying Unbiased, Functional Criteria Allows Selection of Novel Cyclic Peptides for Effective Targeted Drug Delivery to Malignant Prostate Cancer Cells.Pharmaceutics · 2025Article
- CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [European journal of nuclear medicine and molecular imaging · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSince the introduction of PSMA PET/CT with
methodsA retrospective analysis was performed of all 1,704 patients who underwent a
resultsOverall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42-369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml).
conclusionContinuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.